kr502.20
1.14%
Copenhagen, Nov 18, 04:59 pm CET. Closed.
ISIN
DK0060448595
Symbol
COLO B

Coloplast A/S B Stock price

kr502.20
+35.30 7.56% 1M
+97.90 24.21% 6M
-44.20 8.09% YTD
-75.20 13.02% 1Y
-250.00 33.24% 3Y
-667.80 57.08% 5Y
+66.01 15.13% 10Y
+400.13 392.01% 20Y
Copenhagen, Closing price Wed, Nov 18 2026
-5.80 1.14%
ISIN
DK0060448595
Symbol
COLO B

AI Insights on Coloplast A/S B Insights AI Insights on Coloplast A/S B

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Coloplast A/S B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,090 stocks worldwide.

Key metrics

Basic
Market capitalization
kr114.8b
Enterprise Value
kr137.8b
Net debt
-
Cash
-
Shares outstanding
-
Valuation
P/E
37.2
P/S | estimate
4.0 | 3.7
EV/Sales | estimate
4.8 | 4.4
EV/FCF | ex SBC
21.4 | -
P/B
8.6
Dividends
DPS
kr23.00
Yield 1Y | 5Y
4.5% | 2.4%
Growth 1Y | 5Y
4.5% | 3.9%
Payout 1Y | 3Y
168.6% | 126.4%
Increased
3 Years
Financials
Revenue | estimate
kr28.9b | kr31.1b
EBITDA
kr11.9b
EBIT
kr7.4b
Net Income
kr3.1b
Free Cash Flow | ex SBC
kr6.4b | -
Growth
Revenue | estimate
3.8% | 7.4%
EBITDA
30.2%
EBIT
-2.9%
Net Income
-15.5%
Free Cash Flow
23.4%
Margin
Gross
66.5%
EBITDA
41.0%
EBIT
25.7%
Net
10.6%
Free Cash Flow | ex SBC
22.3% | -
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
18.5%
ROIC
14.0%
Debt/Equity
-
More
EPS
kr13.7
FCF per Share
kr28.6
Short interest
-
Employees
17k
Rev per Employee
kr1.7m

Coloplast A/S B Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Coloplast A/S B forecast:

8x Buy
29%
16x Hold
57%
4x Sell
14%

Analyst Opinions

28 Analysts have issued a Coloplast A/S B forecast:

Buy
29%
Hold
57%
Sell
14%

Coloplast A/S B Events

Past Events
NOV
3
Q4 2026 Earnings Call
16 days ago
AUG
18
Q3 2026 Earnings Call
3 months ago
MAY
12
Q2 2026 Earnings Call
6 months ago
APR
24
Coloplast A/S, 2026 Guidance/Update Call, Apr 24, 2026
7 months ago
FEB
6
Q1 2026 Earnings Call
10 months ago
DEC
4
Shareholder/Analyst Call - Coloplast A/S
12 months ago
NOV
4
Q4 2025 Earnings Call
about one year ago

Financial data from Coloplast A/S B

Sep '26
+/-
%
28,941 28,941
4% 4%
100%
- Direct Costs 9,695 9,695
9% 9%
33%
19,246 19,246
2% 2%
67%
- Selling and Administrative Expenses 10,815 10,815
4% 4%
37%
- Research and Development Expense 1,067 1,067
13% 13%
4%
11,876 11,876
30% 30%
41%
- Depreciation and Amortization 4,429 4,429
205% 205%
15%
EBIT (Operating Income) EBIT 7,447 7,447
3% 3%
26%
Net Profit 3,074 3,074
15% 15%
11%

In millions DKK.

Don't miss a Thing! We will send you all news about Coloplast A/S B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.

Head office Denmark
CEO Mr. Rasmussen
Employees 17,083
Founded 1957
Website www.coloplast.dk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today